Kaifeng Kangnuo Pharmaceutical Co. Ltd.

The main purpose of the study is to evaluate the safety and tolerability of single and multiple intravenous administration of different doses of coenzyme I in healthy Chinese adult subjects. The secondary purpose of the study is to evaluate the pharmacokinetic (PK) characteristics of single and multiple intravenous administration of different doses of coenzyme I in healthy Chinese adult subjects.

Primary objective: To evaluate the effectiveness of coenzyme I injection in the treatment of patients with heart failure after acute ST-segment elevation myocardial infarction. Secondary objective: To evaluate the safety of coenzyme I injection in the treatment of patients with heart failure after acute ST-segment elevation myocardial infarction. To evaluate the population pharmacokinetic characteristics of coenzyme I injection in the treatment of patients with heart failure after acute ST-segment elevation myocardial infarction. To determine the optimal dose of coenzyme I injection in the treatment of patients with heart failure after acute ST-segment elevation myocardial infarction. Exploratory objective: To evaluate the changes in biomarkers in patients with heart failure after acute ST-segment elevation myocardial infarction treated with coenzyme I injection.